Placebo QHS and sildenafil and questionnaires + Sildenafil and questionnaire + Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires

Pre-clinicalTerminated

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Penile Cancer

Conditions

Penile Cancer, Erectile Dysfunction, Radical Prostatectomy

Trial Timeline

Aug 6, 2009 → Dec 9, 2020

NCT ID

NCT00955929

About Placebo QHS and sildenafil and questionnaires + Sildenafil and questionnaire + Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires

Placebo QHS and sildenafil and questionnaires + Sildenafil and questionnaire + Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires is a pre-clinical stage product being developed by Pfizer for Penile Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00955929. Target conditions include Penile Cancer, Erectile Dysfunction, Radical Prostatectomy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00955929	Pre-clinical	Terminated	Aug 6, 2009	Dec 9, 2020	Penile Cancer

Competing Products

8 competing products in Penile Cancer

See all competitors

Product	Company	Stage	Hype Score
Avelumab + enfortumab vedotin	Astellas Pharma	Phase 2	52
Pembrolizumab + Standard of care therapy	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
Arm A: Atezolizumab and Radiotherapy + Arm B: Atezolizumab	Roche	Phase 2	52
Dacomitinib	Pfizer	Phase 2	51
Avelumab	Pfizer	Phase 2	51
Cabazitaxel	Sanofi	Phase 2	51
Retifanlimab	Incyte	Phase 2	49

Other Products from Pfizer